Capricor Therapeutics, Inc. (CAPR)
CAPRNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$9.85
+0.8500 (+9.44%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $572.67m
- P/E
- –
- EPS, last 4 quarters
- $-2.45
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.96 to $40.37
- Average volume
- 3.50m
- Previous close
- $9.00
Analysts
8 coveringHold4 buy, 4 hold, 0 sell
Targets a year out average $27.00, +174.1% from here
Earnings
next estimate $-0.6100Next report Nov 10, 2026
Sep 2025
0.0%
Dec 2025
-21.6%
Mar 2026
-7.3%
Jun 2026
-20.7%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$26.29m | -$29.16m | -$36.77m | -$42.95m |
| Net income | -$24.57m | -$30.17m | -$33.94m | -$40.73m |
News
8 latest- Commit To Buy Capricor Therapeutics At $3, Earn 69.5% Annualized Using OptionsBNK Invest · Oct 30, 2026
- Biotech Stocks Facing FDA Decision In November 2026 RTTNews · Oct 29, 2026
- Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data RTTNews · Oct 9, 2026
- Capricor Highlights Two-Year Deramiocel Data as FDA Decision NearsMarketBeat · Oct 7, 2026
- Capricor's Deramiocel Slows Upper Limb Decline In Duchenne Muscular Dystrophy RTTNews · Oct 5, 2026
- Capricor Therapeutics Average Analyst Price Target Rises 12.70% to $24.14Fintel · Oct 1, 2026
- Pre-Market Most Active for Sep 30, 2026 : CAPR, SOFI, NOK, TQQQ, TSLL, SQQQ, SNAP, IBIT, NKE, NIO, ORCL, SGOVNASDAQ.com · Sep 30, 2026
- Biotech Stocks In Focus: Aethlon, Tiziana, Capricor, Firefly & Clearmind RTTNews · Sep 17, 2026
The company
Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for the treatment of Duchenne muscular dystrophy (DMD), evaluated in clinical studies for its potential to preserve skeletal and cardiac muscle function. Capricor is also advancing its proprietary StealthX exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- capricor.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.